Selegiline

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkbp:availability prescription only
generic available
gptkbp:brand Eldepryl
Zelapar
gptkbp:casnumber 14611-51-9
gptkbp:chemical_formula C13 H17 N
gptkbp:class phenethylamine derivative
gptkbp:clinical_trial depression treatment
Parkinson's disease treatment
gptkbp:clinical_use off-label use
adjunct therapy
gptkbp:composed_by from phenethylamine
via reductive amination
gptkbp:contraindication concurrent use of meperidine
concurrent use of SSRIs
gptkbp:developed_by gptkb:Janssen_Pharmaceutica
gptkbp:discovered_by 1970s
gptkbp:duration short-term
long-term
gptkbp:excretion urine
gptkbp:formulation tablets
orally disintegrating tablets
https://www.w3.org/2000/01/rdf-schema#label Selegiline
gptkbp:interacts_with antidepressants
tyramine
dopaminergic drugs
gptkbp:is_a_guide_for depression management
Parkinson's disease management
gptkbp:lifespan 10 hours
gptkbp:mechanism_of_action MAO-B inhibitor
gptkbp:metabolism liver
gptkbp:patient_population gptkb:children
adults
elderly
gptkbp:pharmacokinetics increases dopamine levels
high bioavailability
well absorbed
gptkbp:research_areas gptkb:neurodegenerative_diseases
mental health
gptkbp:route_of_administration oral
gptkbp:safety_features generally well tolerated
risk of serotonin syndrome
risk of hypertensive crisis
gptkbp:side_effect dizziness
nausea
insomnia
dry mouth
gptkbp:used_for gptkb:depression
gptkb:neurodegenerative_diseases
gptkbp:bfsParent gptkb:Sunovion_Pharmaceuticals
gptkb:Monoamine_oxidase_inhibitors
gptkbp:bfsLayer 7